- Home
- MNPR vs ICG Comparison
MNPR vs ICG Comparison
Compare MNPR & ICG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- ICG
- Stock Information
- Founded
- MNPR 2014
- ICG 2017
- Country
- MNPR United States
- ICG China
- Employees
- MNPR N/A
- ICG N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- ICG Semiconductors
- Sector
- MNPR Health Care
- ICG Technology
- Exchange
- MNPR Nasdaq
- ICG Nasdaq
- Market Cap
- MNPR 249.5M
- ICG 230.3M
- IPO Year
- MNPR 2019
- ICG 2023
- Fundamental
- Price
- MNPR $31.73
- ICG $2.09
- Analyst Decision
- MNPR Strong Buy
- ICG Strong Buy
- Analyst Count
- MNPR 5
- ICG 2
- Target Price
- MNPR $59.50
- ICG $9.25
- AVG Volume (30 Days)
- MNPR 18.2K
- ICG 42.8K
- Earning Date
- MNPR 05-13-2025
- ICG 05-22-2025
- Dividend Yield
- MNPR N/A
- ICG N/A
- EPS Growth
- MNPR N/A
- ICG N/A
- EPS
- MNPR N/A
- ICG 0.07
- Revenue
- MNPR N/A
- ICG $53,729,346.00
- Revenue This Year
- MNPR N/A
- ICG N/A
- Revenue Next Year
- MNPR N/A
- ICG $147.04
- P/E Ratio
- MNPR N/A
- ICG $28.17
- Revenue Growth
- MNPR N/A
- ICG 384.54
- 52 Week Low
- MNPR $1.72
- ICG $1.40
- 52 Week High
- MNPR $54.30
- ICG $12.04
- Technical
- Relative Strength Index (RSI)
- MNPR 37.28
- ICG 42.88
- Support Level
- MNPR $34.02
- ICG $2.15
- Resistance Level
- MNPR $36.82
- ICG $2.66
- Average True Range (ATR)
- MNPR 3.54
- ICG 0.35
- MACD
- MNPR -0.71
- ICG -0.03
- Stochastic Oscillator
- MNPR 27.91
- ICG 5.30
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments.